Company: ERAS
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001193125-25-103868
Chunk: 50

Company: Erasca, Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 50
---
.     |     |           |      — |     |        | 85,866 |     |              | 89,593 |     |       | 175,459 |

| (1) | Amounts in this column represent the annual retainers to which the non-employee directors were entitled for 2024. Certain of the non-employee directors who were eligible to receive annual retainers elected to receive those annual retainers in the form of stock options, as described above. The number of options to be awarded was determined based on the Black-Scholes option pricing model on January 1, 2024, which resulted in a Black-Scholes value per share of $1.34. The grant date fair value of the options awarded to the non-employee directors, computed in accordance with FASB ASC 718, was higher than the annual retainers otherwise payable to them. See Note 10 to our consolidated financial statements included in our Annual |

32

| (2) | Represents the grant date fair value of stock options to purchase shares of our common stock computed in accordance with FASB ASC 718 and the incremental value of the annual retainers elected to be received in the form of stock options as follows: Dr. Bristol, $9,229; Mr. Casdin, $6,043; Dr. Harding-Start, $5,823; Ms. Liu, $5,219; and Dr. Multani, $4,834. See Note 10 to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on March 20, 2025, for a description of the assumptions used in valuing our stock options. |

| (3) | Amounts in this column for Dr. Varney include the base salary paid to him for his role as Chair of R&D during 2024 of $86,983 and a matching contribution of $2,610 under our 401(k) plan earned by Dr. Varney in 2024, which is expected to be made by us on behalf of Dr. Varney in 2025. |

The aggregate number of shares subject to stock options outstanding at December 31, 2024 for our non-employeedirectors and Dr. Varney was as follows:

| Name                         |     | Number of      
 securities     
 underlying     
 options        
 outstanding at 
 December 31,   
 2024           |         |